Real-World Evidence for Comparative Outcomes between Innovator and Biosimilar Bevacizumab in Advanced Colorectal Cancers.

ABSTRACT:

Purpose

Generic versions of bevacizumab are commonly used in India in patients with advanced/metastatic colorectal cancers (mCRCs), but there is limited real-world evidence (RWE) about their efficacy in comparison to the innovator bevacizumab.

Methods

Patients diagnosed with mCRC between January 2017 and January 2022 and receiving a combination of chemotherapy and bevacizumab were retrospectively analyzed for demographic variables and survivals. The primary endpoint of the study was the estimation and comparison of median progression-free survival (mPFS) between patients receiving innovator versus generic bevacizumab as first-line therapy (CT1) by the Kaplan-Meier method.

Results

A total of 944 patients were included in the analysis, of whom 652 patients (69%) receive

SUBMITTER: Vaidyanathan A 

PROVIDER: S-EPMC11888807 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature